Immuno-Oncology Cell-Based Assays

Given the complexity of the tumor microenvironment, it is imperative to create in vitro assays that include all major immune cell types a compound may interact with. Investigating with a multicellular phenotypic assay enables us to take various looks at a compound’s responses in platforms specifically designed to mimic the tumor microenvironment. Optimized cell-based assays provide critical information to validate the efficacy of a compound in simple and increasingly complex co-culture assays.

Starting with T cell modulation, we can monitor monitor T cell activation, T cell proliferation, T cell exhaustion, T cell chemotaxis, and cytokine response. We have also developed single cell and co-culture assays to monitor an immunotherapeutic’s interaction with specific cell types such as natural killer cells, macrophages, dendritic cells, neutrophils, and fibroblasts. Available as both 2D and 3D, the assays deliver insights that serve as better predictors for the transition to in vivo studies.

A translational immuno-oncology platform to model the TME

Scientific poster showing a translational immuno-oncology platform to model the TME The Tumor Microenvironment is a complex space. Are you aware of all the immunological mechanisms that could impact your drug development? Download the poster to navigate through the TME

Our immuno-oncology cell based assays include:

Rhiannon Jenkinson, Director of Science at Charles River, discusses the impact of the Tumor Microenvironment on immune-oncology drug development.


A Translational Platform for Immuno-Oncology Drug Discovery

Charles River has developed a translational platform to profile your new agent in in vitro immuno-oncology assays that mimic this complex biology. Our platform is focused on improving translational relevance to support the progression of your compound into in vivo PD studies, confirming immune cell activation, immune cell population changes in the tumor, and cell surface marker changes of immune activation. Your compound can be translated into our in vivo models, including fully validated syngeneic models or humanized mouse models engrafted with human PBMC or CD34+ cells inoculated with tumors from our PDX collection.

Learn more about the platform

Immuno-oncology Discovery and Development FAQs


Have another question or need advice on which model is right for you?

Ask our experts